{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:09:28Z","timestamp":1740136168452,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12935-017-0465-z","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T12:53:34Z","timestamp":1508849614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of \u03b3-irradiation on the induction of bystander killing by genetically engineered ovarian tumor cells: implications for clinical use"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-0972","authenticated-orcid":false,"given":"Jehad","family":"Zweiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-3204","authenticated-orcid":false,"given":"Stephen E.","family":"Christmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/cgt.2010.40","volume":"17","author":"B Sangro","year":"2010","unstructured":"Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 2010;17:837\u201343. doi: 10.1038\/cgt.2010.40 .","journal-title":"Cancer Gene Ther"},{"key":"465_CR2","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1089\/hum.1998.9.17-2595","volume":"9","author":"D Klatzmann","year":"1998","unstructured":"Klatzmann D, Val\u00e9ry CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I\/II study of herpes simplex virus type 1 thymidine kinase \u2018suicide\u2019 gene therapy for recurrent glioblastoma. Hum Gene Ther. 1998;9:2595\u2013604. doi: 10.1089\/hum.1998.9.17-2595 .","journal-title":"Hum Gene Ther"},{"key":"465_CR3","first-page":"5276","volume":"46","author":"FL Moolten","year":"1996","unstructured":"Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1996;46:5276\u201380.","journal-title":"Cancer Res"},{"key":"465_CR4","first-page":"279","volume":"1","author":"FL Moolten","year":"1994","unstructured":"Moolten FL. Drug sensitivity (\u201csuicide\u201d) genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279\u201382.","journal-title":"Cancer Gene Ther"},{"key":"465_CR5","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","volume":"74","author":"GB Elion","year":"1977","unstructured":"Elion GB, Furman PA. Selectivity of action of an antiherpetic agent. Proc Nat Acad Sci USA. 1977;74:5716\u201360.","journal-title":"Proc Nat Acad Sci USA"},{"key":"465_CR6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/1357-4310(96)88774-0","volume":"2","author":"M Caruso","year":"1996","unstructured":"Caruso M. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol Med Today. 1996;2:212\u20137.","journal-title":"Mol Med Today"},{"key":"465_CR7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00046344","volume":"15","author":"LA Martin","year":"1996","unstructured":"Martin LA, Lemoine NR. Direct cell killing by suicide genes. Cancer Metastases Rev. 1996;15:301\u20135.","journal-title":"Cancer Metastases Rev"},{"key":"465_CR8","first-page":"647","volume-title":"Treatment of cancer","author":"P Price","year":"1995","unstructured":"Price P, Sikora K. Treatment of cancer. 3rd ed. London: Chapman & Hall Medical; 1995. p. 647\u201368.","edition":"3"},{"key":"465_CR9","first-page":"2697","volume":"56","author":"W Hamel","year":"1996","unstructured":"Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase\/gancyclovir-mediated apoptotic death of bystander cells. Can Res. 1996;56:2697\u2013702.","journal-title":"Can Res"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/sj.gt.3300379","volume":"4","author":"H Ishii-Morita","year":"1997","unstructured":"Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, et al. Mechanism of \u201cbystander effect\u201d killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244\u201351. doi: 10.1038\/sj.gt.3300379 .","journal-title":"Gene Ther"},{"key":"465_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1566523033347426","volume":"3","author":"C Fillat","year":"2003","unstructured":"Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene\/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13\u201326.","journal-title":"Curr Gene Ther"},{"key":"465_CR12","first-page":"5274","volume":"53","author":"SM Freeman","year":"1993","unstructured":"Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The bystander effect- tumor regression when a fraction of the tumor mass is genetically modified. Can Res. 1993;53:5274\u201383.","journal-title":"Can Res"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/hum.1996.7.2-141","volume":"7","author":"AA Elshami","year":"1996","unstructured":"Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, Albelda SM. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996;7:141\u20138. doi: 10.1089\/hum.1996.7.2-141 .","journal-title":"Hum Gene Ther"},{"key":"465_CR14","first-page":"85","volume":"3","author":"AA Elshami","year":"1996","unstructured":"Elshami AA, Saavedra A, Zhang H, Kucharzuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the \u201cbystander effect\u201d of the herpes simplex virus thymidine kinase\/ganciclovir system in vitro. Gene Ther. 1996;3:85\u201392.","journal-title":"Gene Ther"},{"key":"465_CR15","first-page":"326","volume":"1","author":"SM Freeman","year":"1994","unstructured":"Freeman SM, Ramesh R, Marrogi AJ, Jensen A, Abboud CN. In vivo studies on the mechanisms of bystander effect. Cancer Gene Ther. 1994;1:326\u201332.","journal-title":"Cancer Gene Ther"},{"key":"465_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0140-6736(97)22001-5","volume":"349","author":"SM Freeman","year":"1997","unstructured":"Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet. 1997;349:2\u20133. doi: 10.1016\/S0140-6736(97)22001-5 .","journal-title":"Lancet"},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1089\/hum.1995.6.7-927","volume":"6","author":"SM Freeman","year":"1995","unstructured":"Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, et al. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther. 1995;6:927\u201339. doi: 10.1089\/hum.1995.6.7-927 .","journal-title":"Hum Gene Ther"},{"key":"465_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1165\/ajrcmb.19.2.3123","volume":"19","author":"P Schwarzenberger","year":"1998","unstructured":"Schwarzenberger P, Lei D, Freeman SM, Ye P, Weinacker A, Theodossiou C, et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol. 1998;19:333\u20137. doi: 10.1165\/ajrcmb.19.2.3123 .","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"324","key":"465_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2012.05.023","volume":"28","author":"S Duarte","year":"2012","unstructured":"Duarte S, Carle G, Faneca H, Pedroso de Lima M, Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now? Mini-review. Cancer Letters. 2012;28(324):160\u201370. doi: 10.1016\/j.canlet.2012.05.023 .","journal-title":"Cancer Letters."},{"key":"465_CR20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<267::AID-IJC23>3.0.CO;2-D","volume":"71","author":"RG Vile","year":"1997","unstructured":"Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumor immune response in a non-immunogenic tumour: HSV-TK killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer. 1997;71:267\u201374.","journal-title":"Int J Cancer"},{"key":"465_CR21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1055-3207(18)30258-8","volume":"7","author":"S Singhal","year":"1998","unstructured":"Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am. 1998;7:505\u201336.","journal-title":"Surg Oncol Clin N Am"},{"key":"465_CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13566-015-0239-y","volume":"4","author":"BS Teh","year":"2015","unstructured":"Teh BS, Ishiyama H, Mai W-Y, Thompson TC, Butler EB. Long-term outcome of a phase II trial using immunomodulatory in situ gene therapy in combination with intensity-modulated radiotherapy with or without hormonal therapy in the treatment of prostate cancer. J Radiat Oncol. 2015;4:377\u201386.","journal-title":"J Radiat Oncol"},{"key":"465_CR23","first-page":"17","volume":"5","author":"N Shivapurkar","year":"1999","unstructured":"Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999;5:17\u201323.","journal-title":"Clin Cancer Res"},{"key":"465_CR24","first-page":"195","volume":"311","author":"BW Robinson","year":"1993","unstructured":"Robinson BW. The scientific basis for immunotherapy of human mesothelioma. Eur Resp Rev. 1993;311:195\u20139.","journal-title":"Eur Resp Rev"},{"key":"465_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.2910570524","volume":"57","author":"C Dohring","year":"1994","unstructured":"Dohring C, Angman L, Spangoli G, Lanzaveccchia A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer. 1994;57:75\u20139.","journal-title":"Int J Cancer"},{"key":"465_CR26","first-page":"445","volume":"16","author":"L Xu","year":"2000","unstructured":"Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 2000;16:445\u201354.","journal-title":"Int J Oncol"},{"key":"465_CR27","first-page":"7","volume":"2","author":"M Kuiper","year":"1995","unstructured":"Kuiper M, Peakman M, Farzaneh F. Ovarian tumour antigens as potential targets for immune gene therapy. Gene Ther. 1995;2:7\u201315.","journal-title":"Gene Ther"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1385\/0-89603-484-4:59","volume-title":"Methods in molecular medicine, gene therapy protocols","author":"I Riviere","year":"1997","unstructured":"Riviere I, Sadelain M. Methods for the construction of retroviral vectors and the generation of high-titer producers. In: Robbins P, editor. Methods in molecular medicine, gene therapy protocols. Totowa: Humana Press; 1997. p. 59\u201378. doi: 10.1385\/0-89603-484-4:59 ."},{"key":"465_CR29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0042-6822(88)90101-8","volume":"167","author":"D Markowitz","year":"1988","unstructured":"Markowitz D, Goff A, Bank A. Construction of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400\u20136.","journal-title":"Virology"},{"key":"465_CR30","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1128\/JVI.65.5.2220-2224.1991","volume":"65","author":"A Miller","year":"1991","unstructured":"Miller A. Construction and properties of retrovirus packaging cells based on gibbon ape leukaemia virus. J Virol. 1991;65:2890\u20137.","journal-title":"J Virol"},{"key":"465_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"TM Mosmann","year":"1983","unstructured":"Mosmann TM. Rapid colorimetric assay for cellular growth and survival. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"465_CR32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1258\/0956462991913709","volume":"10","author":"RF Lamont","year":"1999","unstructured":"Lamont RF, Hudson EA, Hay PE, Morgan DJ, Modi V, Ison CA. Comparison of the use of Papanicolaou-stained cervical cytological smears with Gram-stained vaginal smears for diagnosis of bacterial vaginosis in early pregnancy. Int J of STD AIDS. 1999;10:93\u20137.","journal-title":"Int J of STD AIDS"},{"key":"465_CR33","first-page":"177","volume":"16","author":"P Puthavathana","year":"1998","unstructured":"Puthavathana P, Horthongkham N, Kanyok R. Comparison between virus isolation method, Papanicolaou stain, immunoperoxidase stain and polymerase chain reaction in the diagnosis of genital herpes. J Allergy Immunol. 1998;16:177\u201383.","journal-title":"J Allergy Immunol"},{"key":"465_CR34","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.V87.6.2244.bloodjournal8762244","volume":"87","author":"NJ Philpott","year":"1996","unstructured":"Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 1996;87:2244\u201351.","journal-title":"Blood"},{"key":"465_CR35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Necoletti","year":"1991","unstructured":"Necoletti I, Meglorati G, Pagliacci MC, Grignani F, Ricardi C. A rapid simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271\u20139.","journal-title":"J Immunol Methods"},{"key":"465_CR36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00685671","volume":"31","author":"R Gamoussi El","year":"1993","unstructured":"El Gamoussi R, Threadgill MD, Prade M. Relationship between melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazol. Cancer Chemother Pharmacol. 1993;31:277\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"key":"465_CR37","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1089\/hum.1995.6.11-1467","volume":"6","author":"CY Chen","year":"1995","unstructured":"Chen CY, Chang YN, Ryan P, Linscott M, McGarrity GJ, Chiang YL. Effect of herpes simplex thymidine kinase expression levels on ganciclovir -mediated cytotoxicity and the bystander effect. Hum Gene Ther. 1995;6:1467\u201376. doi: 10.1089\/hum.1995.6.11-1467 .","journal-title":"Hum Gene Ther"},{"issue":"Suppl","key":"465_CR38","first-page":"18","volume":"392","author":"FH Gage","year":"1998","unstructured":"Gage FH. Cell therapy. Nature. 1998;392(Suppl):18\u201324.","journal-title":"Nature"},{"key":"465_CR39","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/sj.gt.3300784","volume":"5","author":"RL Touraine","year":"1998","unstructured":"Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVTK\/GCV system and its relationship to a gap junctional communication. Gene Ther. 1998;5:1705\u201311. doi: 10.1038\/sj.gt.3300784 .","journal-title":"Gene Ther"},{"key":"465_CR40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","volume":"4","author":"D Cross","year":"2006","unstructured":"Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4:218\u201327.","journal-title":"Clin Med Res"},{"key":"465_CR41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0167-5699(99)01550-9","volume":"21","author":"S Lal","year":"2000","unstructured":"Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today. 2000;21:48\u201354.","journal-title":"Immunol Today"},{"key":"465_CR42","doi-asserted-by":"publisher","first-page":"16849","DOI":"10.4172\/2157-7412.1000139","volume":"4","author":"P Zarogoulidis","year":"2013","unstructured":"Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, et al. Suicide gene therapy for cancer\u2014current strategies. J Genet Syndr Gene Ther. 2013;4:16849. doi: 10.4172\/2157-7412.1000139 .","journal-title":"J Genet Syndr Gene Ther"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-017-0465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T11:04:04Z","timestamp":1603191844000},"score":1,"resource":{"primary":{"URL":"http:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-017-0465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1186\/s12935-017-0465-z","relation":{},"ISSN":["1475-2867"],"issn-type":[{"type":"electronic","value":"1475-2867"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"article-number":"96"}}